Alkem Laboratories Ltd — earnings calls
1 quarter summarised from transcripts filed with the exchange, every statement cited. Newest first.
Q1 FY27 — transcript filed; not yet summarisedQ4 FY26
Q4 FY26 earnings call
Alkem Laboratories reported Q4 FY26 revenue of INR36,033 million, up 14.6% year-on-year, with EBITDA margin at 14.4% versus 12.4% in the prior year quarter. For FY26, total revenue from operations was INR1,47,123 million, up 13.5%, with EBITDA margin at 20.4% versus 19.4% in FY25. Management discussed the semaglutide launch, the Occlutech acquisition, cost pressures from geopolitical and supply-chain factors, and the planned transition of CEO Vikas Gupta.